Hansoh Pharmaceutical Group Company Limited (FRA:3KY)

Market Cap	23.44B
Revenue (ttm)	1.62B
Net Income (ttm)	578.53M
Shares Out	n/a
EPS (ttm)	0.10
PE Ratio	40.51
Forward PE	42.74
Dividend	0.01 (0.38%)
Ex-Dividend Date	Jul 3, 2025

Volume	2,100
Average Volume	737
Open	3.860
Previous Close	3.840
Day's Range	3.860 - 3.900
52-Week Range	1.880 - 3.900
Beta	n/a
RSI	75.90
Earnings Date	Aug 26, 2025

About FRA:3KY

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Amei...

• Industry: Pharmaceutical Preparations
• Founded: 1995
• Employees: 8,989
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 3KY

Financial Performance

In 2024, FRA:3KY's revenue was 12.26 billion, an increase of 21.35% compared to the previous year's 10.10 billion. Earnings were 4.37 billion, an increase of 33.39%.

Financial numbers in CNY